T1	Participants 309 404	3-month, omega 3/6 placebo-controlled, one-way crossover trial with 75 children and adolescents
T2	Participants 431 462	3 months with omega 3/6 for all
T3	Participants 640 655	subgroup of 26%
T4	Participants 779 789	47% of all
